AlphAIAlphAI — Financial news for AI agents
tradingview.com$SGMT

HC Wainwright & Co. reiterates Buy rating on Sagimet Biosciences, $29 price target

HC Wainwright & Co. reiterated a Buy rating on Sagimet Biosciences (SGMT) with a $29 price target, implying a 217.3% upside from the Oct 2 close of $9.14. The firm cited strong efficacy data for denifanstat, showing a 31.7-lesion reduction in acne patients, and favorable long-term safety data. Recent analyst price targets for SGMT range from $10.71 to $38.

Original reporting
tradingview.com
Published Oct 5, 2026, 10:15 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 10:24 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
HC Wainwright & Co. reiterates Buy rating on Sagimet Biosciences, $29 price target — source image
Source · tradingview.com
Decision brief

The 30-second read

$SGMTBullishLow
01

Why it matters

The rating upgrade could prompt short‑term buying pressure, but the lack of new company‑specific news limits broader market impact.

02

Market read

Analyst rating change with a high target may move SGMT modestly; broader market effect is minimal.

03

What to watch

No discussion of regulatory timeline or competitive landscape.

Relevance 4/10Novelty 2/10Timing: same day

Background

The article reports an analyst's reiterated Buy rating and a new $29 price target for Sagimet Biosciences (SGMT).

Company-level read

Ticker impact

$SGMTBullishMedium confidence
Context

HC Wainwright reiterated a Buy rating and set a $29 price target, implying a 217% upside from the recent close.

Expected impact

potential upward pressure as investors price in the new target

Evidence & confidence

The rating change is a fresh analyst action, but no new operational or financial data were disclosed.

Market effects

Sector

Limited; primarily affects biotech small‑cap sentiment.

Regional

None

Global

Low

Counterpoint

What could challenge this read

The high target may be overly optimistic given limited clinical data.

Key entities

  • company
    Sagimet Biosciences

    Biotech firm developing denifanstat for acne.

  • analyst
    HC Wainwright & Co.

    Equity research firm issuing the rating.

Read at source← All news

Related articles

LowAI 8/10

Ascletis' Strategic Partner Sagimet Announces First Patient Dosed in Phase III U.S. Clinical Trial of Denifanstat (ASC40) for Moderate to Severe Acne – Thailand Business News

Ascletis Pharma Inc.'s partner, Sagimet Biosciences, has dosed the first patient in a Phase III U.S. trial of denifanstat (ASC40) for moderate to severe acne. The trial aims to enroll 800 patients. Ascletis' prior Phase III trial in China showed ASC40 was more effective than FDA-approved treatments, with 18.6% treatment success vs. 9.4% for sarecycline and 6.7% for doxycycline.

thailand-business-news.com
$SGMTMedAI 8/10

Sagimet Biosciences (SGMT) Launches Phase 3 AURORA Trial for Acn

Sagimet Biosciences (SGMT) started its Phase 3 AURORA trial for denifanstat, a drug for moderate to severe acne. The trial's success could lead to regulatory approval. SGMT has a high P/S ratio of 58.8x, reflecting growth expectations. The company has a GF Score of 34, indicating strong financial stability but weak profitability and growth. Insider selling and cautious institutional sentiment are noted.

gurufocus.com
LowAI 8/10

David Happel of Sagimet talks about what denifanstat must prove in the U.S. | 2026 Fall Clinical Derm

Sagimet Biosciences has started a U.S. phase 3 trial for denifanstat, an acne treatment. CEO David Happel expects results to mirror Chinese data, showing 55.6-57.8% treatment success. The drug reduces inflammatory lesions by 75.8-78.1% and offers long-term flexibility. Happel believes positive U.S. results will gain acceptance from dermatologists and payers.

managedhealthcareexecutive.com
$SGMTMedAI 8/10

Sagimet presents 52-week acne drug data at dermatology meeting

Sagimet Biosciences (NASDAQ:SGMT) announced 52-week clinical results for denifanstat, showing 57% success rate and significant lesion reduction. The data will be presented at the 2026 Fall Clinical Dermatology Conference. The drug is being developed for moderate to severe acne, with a U.S. Phase 3 trial underway. Ascletis holds rights in China, where a New Drug Application was submitted in December 2025.

investing.com